Skip to main content
Midas Edge

IRADIMED CORP

For the period ended Dec 31, 2024. Filed Mar 6, 2025.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Mar 6, 2025

IRMD$86.94+0.7%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Statements of Stockholders’ Equity

​​​​​​​​​​​​​​​
​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​
​ · ​ · ​ · ​ · ​ · ​ · ​ · Additional · ​ · ​ · ​ · ​ · ​
​ · ​ · Common Stock · ​ · Paid-in · ​ · Retained · ​ · Stockholders’
​ · Shares · Amount · Capital · Earnings · Equity
Balances, December 31, 202212,591,004$1,259$26,407,446$47,264,282$73,672,987
Net income—​​—​​—​​17,192,776​​17,192,776
Dividends declared—​​—​​—​​(21,198,904)​​(21,198,904)
Stock-based compensation expense—​​—​​2,186,909​​—​​2,186,909
Net share settlement of restricted stock units41,879​​4​​(610,345)​​—​​(610,341)
Net share settlement of performance based stock units​6,430​​—​​—​​—​​—
Exercise of stock options21,000​​2​​176,735​​—​​176,737
Balances, December 31, 202312,660,313$1,265$28,160,745$43,258,154$71,420,164
Net income—​​—​​—​​19,234,026​​19,234,026
Dividends declared—​​—​​—​​(5,701,429)​​(5,701,429)
Stock-based compensation expense—​​—​​2,524,536​​—​​2,524,536
Net share settlement of restricted stock units40,109​​5​​(557,090)​​—​​(557,085)
Net share settlement of performance based stock units​6,428​​1​​(131,076)​​—​​(131,075)
Exercise of stock options3,010​​—​​29,619​​—​​29,619
Balances, December 31, 202412,709,860$1,271$30,026,734$56,790,751$86,818,756

See accompanying notes to financial statements.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.